Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...
SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
“Whoopsie daisy! Yoo-hoo!” Lana Del Rey is back, all right. The singer-songwriter has officially returned with “White Feather Hawk Tail Deer Hunter,” off her upcoming album, Stove. “White Feather Hawk ...
Recursive language models (RLMs) are an inference technique developed by researchers at MIT CSAIL that treat long prompts as an external environment to the model. Instead of forcing the entire prompt ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
James is a published author with multiple pop-history and science books to his name. He specializes in history, space, strange science, and anything out of the ordinary.View full profile James is a ...
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...
Recursion Pharmaceuticals uses AI to improve the process of discovering and developing drugs, making it easier and more cost-effective. Most medicines that enter clinical trials never reach the market ...
Recursion Pharmaceuticals (NASDAQ:RXRX) stock is one of those lesser-known mid-cap biotech plays that investors may be interested in buying on weakness, primarily because of its dealings with the ...
During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results